Fig. 2From: A multi-institutional feasibility study of S-1/oxaliplatin plus bevacizumab in patients with advanced/metastatic colorectal cancer: the HiSCO-02 prospective phase II studyKaplan-Meier curves for progression-free survival (PFS); the median PFS was 9.2 months (95 % confidence interval: 7.6–10.8) N. at risk, number at riskBack to article page